What is HC Wainwright’s Forecast for MLYS FY2029 Earnings?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Investment analysts at HC Wainwright boosted their FY2029 EPS estimates for Mineralys Therapeutics in a report issued on Monday, March 16th. HC Wainwright analyst M. Caufield now expects that the company will earn $1.56 per share for the year, up from their prior forecast of $1.54. HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ FY2030 earnings at $4.55 EPS.

Several other research analysts also recently commented on MLYS. Bank of America boosted their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Stifel Nicolaus boosted their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, Jefferies Financial Group restated a “hold” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Friday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.14.

Mineralys Therapeutics Trading Down 2.8%

NASDAQ MLYS opened at $25.02 on Tuesday. The firm’s 50 day simple moving average is $30.04 and its 200 day simple moving average is $35.79. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -10.56 and a beta of 0.57. Mineralys Therapeutics has a 1 year low of $10.44 and a 1 year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17.

Institutional Investors Weigh In On Mineralys Therapeutics

Large investors have recently modified their holdings of the stock. State Street Corp raised its holdings in shares of Mineralys Therapeutics by 144.4% in the 4th quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after purchasing an additional 1,881,976 shares during the period. Farallon Capital Management LLC bought a new position in Mineralys Therapeutics during the third quarter valued at $63,442,000. Price T Rowe Associates Inc. MD grew its holdings in Mineralys Therapeutics by 6,097.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock valued at $48,089,000 after purchasing an additional 1,303,737 shares during the period. Holocene Advisors LP purchased a new stake in Mineralys Therapeutics in the third quarter worth $45,708,000. Finally, Janus Henderson Group PLC increased its position in Mineralys Therapeutics by 6,012.8% in the fourth quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company’s stock worth $44,005,000 after buying an additional 1,193,417 shares during the last quarter. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Insiders Place Their Bets

In other Mineralys Therapeutics news, CEO Jon Congleton sold 16,236 shares of Mineralys Therapeutics stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.62, for a total value of $529,618.32. Following the sale, the chief executive officer owned 639,151 shares of the company’s stock, valued at approximately $20,849,105.62. The trade was a 2.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Adam Scott Levy sold 10,758 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.14, for a total transaction of $345,762.12. Following the completion of the transaction, the chief financial officer owned 8,638 shares in the company, valued at approximately $277,625.32. The trade was a 55.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 363,325 shares of company stock valued at $12,298,347. Insiders own 33.24% of the company’s stock.

Key Headlines Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Company said it advanced regulatory review of its hypertension candidate and reported 2025 results, which supports the clinical/regulatory story underpinning long‑term value. Mineralys reports 2025 results, advances hypertension drug review
• Positive Sentiment: HC Wainwright raised FY2030 and FY2029 EPS estimates and maintains a “Buy” rating with a $56 target, signaling rising sell‑side expectations for multi‑year profitability (FY2030 EPS raised to $4.55; FY2029 to $1.56).
• Positive Sentiment: Recent quarterly report (Mar 12) beat consensus on EPS: reported ($0.40) vs. consensus ($0.57), showing better near‑term operating performance than modeled by some analysts.
• Neutral Sentiment: Institutions have been active — several funds added positions and Goldman Sachs materially increased its stake — which can lend stability but also reflects varied institutional views; consensus price target remains elevated versus current trading levels.
• Negative Sentiment: Insider selling: Director/officer David Malcom Rodman has sold multiple large blocks in March (most recently 6,348 and 14,058 shares), which may worry investors about near‑term insider conviction. MLYS Insider Selling
• Negative Sentiment: Technical/price pressure: shares are trading below the 50‑day and 200‑day moving averages and have declined today, reflecting short‑term selling despite positive fundamentals; consensus near‑term EPS remains negative (market consensus ~ -$4.23 for the current year), keeping risk elevated for investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.